Wall Street loves a good upgrade, especially when the stock has already doubled and the analyst can

Eikon Therapeutics, Inc. (EIKN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference

MILLBRAE, Calif., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (“Eikon

MILLBRAE, Calif., Aug. 26, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (“Eikon”

Nasdaq: NYAX rose 13.9% on Tuesday after announcing acquisition of IPS Group Inc. for $350 million.

Eikon Therapeutics NASDAQ: EIKN outlined its development strategy for selective PARP1 inhibitors and

Eikon Therapeutics, Inc. (EIKN) Discusses Advances in PARP1 Biology and Next-Generation PARP Inhibit

Dow Jones up 200 points on Wed. Estee Lauder & other top stocks record gains after reporting str

Chairman and Chief Executive Officer, Roger M. Perlmutter, M.D., Ph.D., will participate in a key op

Wedbush analyst Robert Driscoll maintains Eikon Therapeutics (NASDAQ:EIKN) with a Underperform an

MILLBRAE, Calif., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (“Eikon”

Selected 0.60 mg/m2 as the single dose for the TeLuRide-006 study going forward for patients randomi

MILLBRAE, Calif., Aug. 10, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (“Eikon”

Eikon Therapeutics' (NASDAQ: EIKN - Get Free Report) lock-up period will end on Tuesday, August 4th.

US stocks mixed in midday trading, Nasdaq falls 0.48%, Dow up 0.19%, S&P 500 down 0.23%. Consume

Dow Jones up 400 points on Monday. Baker Hughes Co (BKR) shares rise after positive earnings and tec

"Treating the first patient in TeLuRide-008 is a significant milestone for Eikon as we continue

MILLBRAE, Calif., July 27, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (Eikon),

Presentations to cover updates across Eikon's clinical pipeline including:  Updated data from TeLuRi

Gainers Pulsenmore (NASDAQ:PLSM) shares increased by 171.2% to $10.47 during Monday's pre-marke

Gainers Shuttle Pharmaceuticals (NASDAQ:SHPH) shares moved upwards by 66.9% to $6.31 during Thursda

Eikon Therapeutics, Inc. (NASDAQ:EIKN) ("Eikon"), a late-stage clinical biopharmaceutical co

Addition reflects Eikon's progress as a publicly traded company and increasing visibility within the

Eikon Therapeutics is initiated with a cautious buy, leveraging industry-leading management and a ro

MILLBRAE, Calif., June 08, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (“Eikon”

TeLuRide-005, a Phase 2 trial of EIK1001 in first-line patients with stage 4 NSCLC completed enrollm

Presentations to cover progress across Eikon's most advanced clinical-stage programs Updated data wi

ZBRA, VSTS, AMBQ, VPG, BAK, PACS, LOT, EIKN, DDD, WEN, SIBN post significant gains on better-than-ex

Wedbush analyst Robert Driscoll maintains Eikon Therapeutics (NASDAQ:EIKN) with a Underperform an

Eikon Therapeutics (NASDAQ:EIKN) reported quarterly losses of $(2.46) per share which beat the analy

MILLBRAE, Calif., May 11, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (“Eikon”)

U.S. stock futures mixed with Dow futures down 0.1%. Domino's Pizza misses earnings expectations

Wedbush analyst Robert Driscoll reiterates Eikon Therapeutics (NASDAQ:EIKN) with a Underperform a

Closed upsized initial public offering in February 2026, raising $381 million in gross proceeds Comp

EIKN (NASDAQ: EIKN - Get Free Report) has received an average rating of "Moderate Buy" from the seve

Cantor Fitzgerald analyst Imogen Mansfield initiates coverage on Eikon Therapeutics (NASDAQ:EIKN)

JP Morgan analyst Brian Cheng initiates coverage on Eikon Therapeutics (NASDAQ:EIKN) with a Overw

Wall Street analysts changed outlook on top names. For all changes, upgrades, downgrades and initiat

B of A Securities analyst Jason Zemansky initiates coverage on Eikon Therapeutics (NASDAQ:EIKN) w

Mizuho analyst Joseph Catanzaro initiates coverage on Eikon Therapeutics (NASDAQ:EIKN) with a Out

Morgan Stanley analyst Sean Laaman initiates coverage on Eikon Therapeutics (NASDAQ:EIKN) with a

Wedbush analyst Robert Driscoll initiates coverage on Eikon Therapeutics (NASDAQ:EIKN) with a Und

The U.S. is reportedly poised for a wave of significant IPOs, with Goldman Sachs projecting proceeds